Thank us. We're be excited quarter. our you, for announce results able Kimberly. thank you to second for morning, and Good joining everyone, very to
our The YUTIQ two first our product marked quarter launches quarter and full of DEXYCU. second
for reminder, eager upon shared quarter Managers Key and across revenue launch the for retinal a or U.S. previous call As initial surgery weeks accounted are for force YUTIQ. our and following centers May performance and XX% surgeons our first uveitis for our only and earnings for cataract specialists came launch, a high YUTIQ specialist sales to on and trained March XX few and YUTIQ well continue February DEXYCU in KAMs DEXYCU volume call Account DEXYCU for the
product our U.S. launches these very innovative momentum second YUTIQ happy focused we quarter DEXYCU the physicians. treatments strong the are of such ongoing have and We for and value to reach are truly of tremendous patients that expanding and on with commercial
eye. Let treatment affecting fluocinolone posterior segment X.XX chronic start of YUTIQ me acetonide the implant with non-infectious uveitis intravitreal the of milligrams first the or for
consistently primarily to reminder, has and release consistent up for existing wet Anti-VEGF or Lucentis. the capillaries therapies such of time Eylea short retinal as a often drug differentiated used YUTIQ first years. three AMD. of edema, amount characterized Please up to a months. profile These seen posterior steady XX a is this micro designed tiny is a segment product YUTIQ the one to peaks is for administration is acting delivers was that level intravitreal such compared eye important, highly drug valleys that consistently a it frequently steroids therapies blood And fluocinolone, are As its as uveitis to and because macular back line and of and remarkably diseases by of avoids leaking insert and diabetic well-known occlusion vein fluid, dose a unlike corticosteroids. steady note, the other micro diseases
by For eye, indicated as Anti-VEGF inflammation posterior the also in caused uveitis you therapy eye. as segment known back however, uveitis of the is the is of not the
First line highly which segment inflammatory. uveitis in effective therapy eye posterior steroids, for is are
we need period the is excited of to market dose that YUTIQ, unpredictable And critical expectations. very in blinding The of and a we consistent initial to exceeding which unpredictable flares. uveitis number micro this even provide to long a of potentially devastating, is goal inflammation, were treating earlier which therapy the of uveitis in more is over our about Because important this, uveitis of YUTIQ a comes can the to prevent provide That's reduce are a critically year. time excited treatment trajectory introduce flares. launch steroid internal to
own used blinding have in YUTIQ out Physicians showed data treat sight both XX, have patients, YUTIQ and months specialists key as As our acclaimed XX as to to among physicians the uveitis YUTIQ reduction management key by now term XX% flares as of those of July approximately long that from to of of account driver positive compelling top well recurrences a been target highly doctors Feedback clinical our visited uveitis been to continue in from it. physicians been have who practices. widely has include a patients the these team. their potentially
doctors camps the initial meetings great interest given success have with Our giving in had high YUTIQ.
that to two is market for representatives organization increasing to in during contract month demand, positive sales sales our potential to YUTIQ physician plan this through more more efforts. quota further number campaign support our YUTIQ remain month. ordering our physicians also dedicate over of July upward resources To YUTIQ hiring We will by strong. period growth of rapid trajectory showing interest the maximize and high and we expect
may ramps continues, As our additional we representatives. hire
under quarter best-in-class permanent process we an and be This had prior take is for a JXXXX, than J received YUTIQ allowing XXXX. On earlier have the earlier will reimbursement assignment in the anticipated. early we front, code milestone to policy effect October approval which more CMS than reimbursement of previously X, effect streamlined, a key specific one
and have being for few authorization More its front. and reimbursement with review. academic use on XX approved approved labeled today access EyePoint a We seen continue minimal YUTIQ is rejections the very for We've formula under eligible to positive reimbursement to in need indication assist we've financial ensure requirements. than program pending receive assistance. patients for eight peer for with YUTIQ available to seen YUTIQ prior support a
that medical YUTIQ three highlighting We XXth data July, And of was were data In conference proud data Specialist lower positive the and Data Phase showed education of American presented a versus rate Meeting improvements treated Chicago than promising our than visual of for presentations the supportive Society XX.X% YUTIQ at that a assistance in month randomized lower in in from clinical YUTIQ. follow-up the less compared acuity eyes Sham recurrence with to Annual Scientific a respectively, Sham. best of the and at as safety of affairs significantly initiative. corrected part have XX.X% X.XXX. oral eyes in XX p III adjunct to the included Retinal value we need trials
Based is going Feedback devastating the medical options and treatment these balancing YUTIQ was applauding by community the this to comparable bugs continued YUTIQ study, patients term of prospects advocacy patients blinding treating disease. again spot forward. rescue in Sham results durable deny serious Sham. positive Physicians and meeting recall about care. very of the with potentially And of activity three favorable on market the in long YUTIQ'S medication an aside cannot and you real treating on this safety. a majority and solid sweet we vast for eye for when had medication remarkable data the years. standard the of Since finding YUTIQ positive extremely disease, that remained received for the up this advance revenue exceptionally rescue bullish means often share Now disease lack members
expect intraocular to end from This steroids % reception for for time highly Like a care standard commonly inflammation, turn me of post-operative post eye and cataract can at convenient that positive as a use single drop surgery and up of the release DEXYCU the for to ease cataract avoids Let the product inflammation. become complicated now as surgery results. clinical dexamethasone very and profile, a drug its eyedrops. of injection week particular executed treating suspension days. tapered XX we given eye DEXYCU steroids it administered Dexamethasone YUTIQ, that burdensome such initial associated over effective surgery, of on in of physicians with and provides based schedule four used DEXYCU. supportive
the procedure In be it’s easily effective administration. the time also suite, required vital drug safe, to with minimal administered not or surgery that complete can but be cataract any and only administered,
any we want that Physicians they X surgeries XXXX, to X.X extremely often slow performed were there perform new down. to to cataract surgeons and expect of not in Remember, them continue XX over huge a do procedure minutes, to busy. grow. market. These are And procedures million in surgery volume cataract
I have They from and speed, patient. move these convenience, to patient want hassles very of as quickly to control and want Just safety, administer to surgeons personally can tell needs. five It surgery. the they XX of that surgery to cataract attended reference, days only can administer I because compliance no to you takes patient efficacy, seconds with on XXX% the meets to DEXYCU it the medication average patient. they get XX ensure these DEXYCU approximately end not reimbursement
simple injection one DEXYCU, after with and efficacy see safety of continuing why interest on trained high its ease data to DEXYCU. we use coupled That with are now data are of excellent is surgeons
and Surgery teams through Center certified launch application sampling trained dedicated being on camps focused program DEXYCU a and Our have on surgeons ASC to administration to Ambulatory that DEXYCU prior phased cleared preparation, and of or their to are ensure fully the product cataract purchase. been the support
As receive due their its DEXYCU, surgeries. end injection and surgeon day’s time non-disruptive the who extremely the use and we of to allowing cataract process to cataract continue schedule from earlier, supportive intent feedback quick positive have surgeons, I at surgery with remain the on to to administration noted expressed
to launch leaders of top a certification surgeons of ability physicians Of DEXYCU I broader allow where first, launch. with highest certification product – certified me surgeons the to strategy our over and over XXX group its before we rolled purchase being for and quality and since and to over opinion initial training are consisted ASCs, position the have which to out over training – sampling. excuse the make completed mentioned have greatest phase now inroads, our XXX key XXX program to
with the to have clinical having office over told program. and soon fast acting professionals significant on majority patients Surgeons Over These predominantly a XXXX of our with discuss been have been day in seen staffs since launch, with DEXYCU, medical again, them certification samples us DEXYCU. where exhibited efficacy our And by remarkable have injected called they studies, patients have how part of and that’s impressed eight, inflammation. return so on surgery. activity the are after they X,XXX zero
very Safety with and consistent is our IOP have actual the adverse numbers of key reports below including events which X% no the elevation, XX%, low to clinical to of label, label one incidence pay low X% in which of about to than real common X%. very to side label less clinical of a effects corneal is attention numbers edema setting physicians and world X% the been our
XX treatment post-surgical XX within and to and J-Code drops. easier physician statistical compound regimen effects steroids significance eye so day dissolves to eight place these now, drugs, fast is other it because alternative step relief ahead a to reaches potentially patient DEXYCU steroids is been reimbursement far DEXYCU for side or options transient. eye the hours, versus have and like compared inflammation patient devices on in clearly Since a drops much administer,
feedback our and on be And been can has look very and you at to that on urge corporate Twitter Physician firsthand positive. our feed. testimonials website www.eyepointpharma.com at viewed video I patient our
rejected that The if product quickly difference issues has CMS or been a the secured payment. J-Code. it how can queue have given an is Reimbursement is make project by permanent the for reimbursement code a and specific to reimbursed enormous is it and
administered are and systems, Because because well administered Medicare J-Code payer including plans Medicare has Medicare by fee-for-service, private virtually plans commercial CMS. a Advantage recognized it’s by very as universally payers. which become all by private A important fee-for-service is has as by Advantage Medicare administered by straightforward. plans, J-Code, and other again reimbursement DEXYCU payers which is commercial
because are surgery reimbursed a Other under revenue, skeptical lost not often payers might reimbursement have by some experience to ASCs to some add been and causing payers, private has made the in the is past new drugs product label. has about consistently authorization some C-Code, for products. which Commercial made of for prior not which reimbursement have which ocular they accepting recognized the them
process been J-Code commercial for seeing Advantage alleviated streamline the XXX% with the and of plan on concerns have investigations presented ASCs XX% and fee-for-service. patients and proceeds them approved Their benefit pickup educated DEXYCU we gone. and being now we’ve risk As are on Medicare results Medicare showing volume largely over reimbursement
reminder, providers under a with requirements model under a maintains sold Revenues logistics agreement. the third model, inventory was Cardinal recognized per As which our party sale certain to upon title DEXYCU Health. the title
Given with help demand. on may product additional these Scott provide always feedback clarify complexities, and DEXYCU. Reporting demand color be sales model for this to under physician Sales trajectories aligned not physician will
Due to launch XXXX. at generate the Health of title in the in inventory Cardinal product first the late time revenue quarter stocking DEXYCU under second our quarter, adequate did model the by distributor mid-March, of the not during
paid be down were at ambulatory As for and center the surgical claims then inventory. working each surgery to waiting we physicians training and staff DEXYCU
we shown Our the being in increasingly third seeing early DEXYCU after following data, seeing clinical DEXYCU’s patients the injected now our the We strong sampling training significant have July X,XXX prospects, certification, ASCs and and been are have efforts seeing remain in reimbursed demand are share DEXYCU very physicians claims and showing quarter. increase results. completion especially orders market and of for the are surgical a with and bullish revenue about
now new discuss Jones, our Scott our the me Chief Officer, turn over Commercial to commercial to further. initiatives Let call
of a as KOL have in Scott? many join track to excited experience, organizations. team We’re of he Scott commercial and leading and in ophthalmology a our proven June, record brings relationships pair wealth success
